Comparison of efficacy and safety of paste formulations of firocoxib and phenylbutazone in horses with naturally occurring osteoarthritis

Journal of the American Veterinary Medical Association

Volumn 232, Issue 1, 2008, Pages 91-97

  Doucet, Michèle Y ^a   Bertone, Alicia L ^b   Hendrickson, Dean ^c   Hughes, Faith ^d   MacAllister, Charles ^e   McClure, Scott ^f   Reinemeyer, Craig ^g   Rossier, Yves ^a   Sifferman, Roger ^h   Vrins, André A ^a   White, Gary ⁱ   Kunkle, Bruce ^j   Alva, Roberto ^j   Romano, Davida ^j   Hanson, Peter D ^j  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b OHIO STATE UNIVERSITY   (United States)

^c USA   (United States)

^d Peterson and Smith Equine Hospital   (United States)

^e OKLAHOMA STATE UNIVERSITY   (United States)

^f IOWA STATE UNIVERSITY   (United States)

^g East Tennessee Clinical Research Inc   (United States)

^h Bradford Park Veterinary Hospital   (United States)

ⁱ Sallisaw Equine Clinic   (United States)

^j BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

3 (CYCLOPROPYLMETHOXY) 4 (4 METHYLSULFONYLPHENYL) 5,5 DIMETHYLFURANONE; 3-(CYCLOPROPYLMETHOXY)-4-(4-METHYLSULFONYLPHENYL)-5,5-DIMETHYLFURANONE; DRUG DERIVATIVE; GAMMA BUTYROLACTONE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLBUTAZONE; SULFONE; UNCLASSIFIED DRUG;

ANIMAL; ANIMAL DISEASE; ANIMAL LAMENESS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HORSE; HORSE DISEASE; HOSPITALIZATION; JOINT CHARACTERISTICS AND FUNCTIONS; MALE; OSTEOARTHRITIS; PATHOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME;

4-BUTYROLACTONE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FEMALE; HORSE DISEASES; HORSES; LAMENESS, ANIMAL; MALE; OSTEOARTHRITIS; PHENYLBUTAZONE; RANGE OF MOTION, ARTICULAR; SEVERITY OF ILLNESS INDEX; SULFONES; TIME FACTORS; TREATMENT OUTCOME;

ANIMALIA; EQUIDAE;

EID: 38049117830     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.232.1.91     Document Type: Conference Paper

References (35)

1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232-235.
2. MacAllister CG. Effects of toxic doses of phenylbutazone in ponies. Am J Vet Res 1983;44:2277-2279.
3. Collins LG, Tyler DE. Experimentally induced phenylbutazone toxicosis in ponies: description of the syndrome and its prevention with synthetic prostaglandin E2. Am J Vet Res 1985;46:1605-1615.
4. Meschter CL, Gilbert M, Krook L, et al. The effects of phenylbutazone on the intestinal mucosa of the horse: a morphological, ultra-structural and biochemical study. Equine Vet J 1990;22:255-263.
5. Brideau C, Van Staden C, Chan CC. In vitro effects of cyclooxygenase inhibitors in whole blood of horses, dogs, and cats. Am J Vet Res 2001;62:1755-1760.
6. Hunter DJ, Felson DT. Osteoarthritis. BMJ 2006;332:639-642.
7. Bergh MS, Budsberg SC. The coxib NSAIDs: potential clinical and pharmacologic importance in veterinary medicine. J Vet Intern Med 2005;19:633-643.
8. Millis DL, Weigel JP, Moyers T, et al. Effect of deracoxib, a new COX-2 inhibitor, on the prevention of lameness induced by chemical synovitis in dogs. Vet Ther 2002;3:453-464.
9. Royals SR, Farese JP, Milner RJ, et al. Investigation of the effects of deracoxib and piroxicam on the in vitro viability of osteosarcoma cells from dogs. AmJ Vet Res 2005;66:1961-1967.
10. Sessions JK, Reynolds LR, Budsberg SC. In vivo effects of carprofen, deracoxib, and etodolac on prostanoid production in blood, gastric mucosa, and synovial fluid in dogs with chronic osteoarthritis. Am J Vet Res 2005;66:812-817.
11. Tomlinson JE, Blikslager AT. Effects of cyclooxygenase inhibitors flunixin and deracoxib on permeability of ischaemic-injured equine jejunum. Equine Vet J 2005;37:75-80.
12. McCann ME, Andersen DR, Zhang D, et al. In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis. Am J Vet Res 2004;65:503-512.
13. McCann ME, Rickes EL, Hora DE, et al. In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in cats with lipopolysaccharide- induced pyrexia. Am J Vet Res 2005;66:1278-1284.
14. Kvaternick V, Pollmeier M, Fischer J, et al. Pharmacokinetics and metabolism of orally administered firocoxib, a novel second generation coxib, in horses. J Vet Pharmacol Ther 2007;30:208-217.
15. Pollmeier M, Toulemonde C, Fleishman C, et al. Clinical evaluation of firocoxib and carprofen for the treatment of dogs with osteoarthritis. Vet Rec 2006;159:547-551.
16. Hanson PD, Brooks KC, Case J, et al. Efficacy and safety of firocoxib in the management of canine osteoarthritis under field conditions. Vet Ther 2006;7:127-140.
17. FDA-CVM. Freedom of information summary. EQUIOXX oral paste - 0.82% firocoxib (w/w). NADA 141-253. Rockville, Md: FDA, 2005.
18. Wright IM, Kidd L, Thorp BH. Gross, histological and histomorphometric features of the navicular bone and related structures in the horse. Equine Vet J 1998;30:220-234.
19. Stashak TS, Hill C. Chapter 2: conformation and movement. In: Stashak TS, ed. Adam's lameness in horses. 5th ed. New York: Lippincott Williams & Wilkins, 2002;73-112.
20. Stashak TS. Chapter 3: examination for lameness. In: Stashak TS, ed. Adam's lameness in horses. 5th ed. New York: Lippincott Williams & Wilkins, 2002;113-184.
21. Mcllwraith CW. Chapter 7: diseases of joints, tendons, ligaments, and related structures. In: Stashak TS, ed. Adam's lameness in horses. 5th ed. New York: Lippincott Williams & Wilkins, 2002;459-644.
22. Muir WW III, Woolf CJ. Mechanisms of pain and their therapeutic implications. J Am Vet Med Assoc 2001;219:1346-1356.
23. Lu ZH, Xiong XY, Zhang BL, et al. Evaluation of 2 celecoxib derivatives: analgesic effect and selectivity to cyclooxygenase-2/1. Acta Pharmacol Sin 2005;26:1505-1511.
24. Satyanarayana PS, Jain NK, Singh S, et al. Effect of selective inhibition of cyclooxygenase-2 on lipopolysaccharide-induced hyperalgesia. Inflammopharmacology 2004;12:57-68.
25. Fabricio AS, Veiga FH, Cristofoletti R, et al. The effects of selective and nonselective cyclooxygenase inhibitors on endothelin1-induced fever in rats. Am J Physiol Regul Integr Comp Physiol 2005;288:R671-R677.
26. Dembo G, Park SB, Kharasch ED. Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans. Anesthesiology 2005;102:409-415.
27. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science 2000;288:1765-1769.
28. Dirks J, Moiniche S, Hilsted KL, et al. Mechanisms of postoperative pain: clinical indications for a contribution of central neuronal sensitization. Anesthesiology 2002;97:1591-1596.
29. Battisti WP, Katz NP, Weaver AL, et al. Pain management in osteoarthritis: a focus on onset of efficacy - a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials. J Pain 2004;5:511-520.
30. Collins LG, Tyler DE. Phenylbutazone toxicosis in the horse: a clinical study. J Am Vet Med Assoc 1984;184:699-703.
31. Lees P. Pharmacology of drugs used to treat osteoarthritis in veterinary practice. Inflammopharmacology 2003;11:385-399.
32. Griffin MR, Stein CM, Graham DJ, et al. High frequency of use of rofecoxib at greater than recommended doses: cause for concern. Pharmacoepidemiol Drug Saf 2004;13:339-343.
33. Lascelles BD, Blikslager AT, Fox SM, et al. Gastrointestinal tract perforation in dogs treated with a selective cyclooxygenase-2 inhibitor: 29 cases (2002-2003). J Am Vet Med Assoc 2005;227:1112-1117.
34. Nielsen OH, Ainsworth M, Csillag C, et al. Systematic review: coxibs, non-steroidal anti-inflammatory drugs or no cyclooxygenase inhibitors in gastroenterological high-risk patients? Aliment Pharmacol Ther 2006;23:27-33.
35. DeMaria AN, Weir MR. Coxibs-beyond the GI tract: renal and cardiovascular issues. J Pain Symptom Manage 2003;25: S41-S49.